Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (vol 9, pg 144, 2024)

被引：0
|
作者：
Magnani, Jared W. [1 ]
Allen, Norrina B. [2 ]
机构：
[1] Univ Pittsburgh, Dept Med, 609 Forbes Ave,2nd Floor, Pittsburgh, PA 15213 USA
[2] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL USA
来源：
JAMA CARDIOLOGY | 2024年 / 9卷 / 07期
关键词：
D O I：
10.1001/jamacardio.2024.1234
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：674 / 674
页数：1
相关论文
共 42 条
  • [31] Which formula for estimating glomerular filtration rate is the better predictor of outcomes in heart failure with preserved ejection fraction? An analysis from the I-Preserve trial
    Pozzi, A.
    Jhund, P. S.
    Damman, K.
    Massie, B. M.
    Carson, P.
    Komajda, M. R.
    Mckelvie, R.
    Zile, M. R.
    Anand, I. S.
    Mcmurray, J. J. V.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 2 - 2
  • [32] Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
    Inzucchi, Silvio E.
    Claggett, Brian L.
    Vaduganathan, Muthiah
    Desai, Akshay S.
    Jhund, Pardeep S.
    de Boer, Rudolf A.
    Hernandez, Adrian F.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    Verma, Subodh
    Han, Yaling
    Saraiva, Jose F. Kerr
    Bengtsson, Olof
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (12): : 869 - 881
  • [33] Association of serial Kansas City Cardiomyopathy Questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials (vol 2, pg 1315, 2017)
    Pokharel, Y.
    Khariton, Y.
    Tang, Y.
    [J]. JAMA CARDIOLOGY, 2018, 3 (02) : 181 - 181
  • [34] Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction A Secondary Analysis of 2 Randomized Clinical Trials
    Pokharel, Yashashwi
    Khariton, Yevgeniy
    Tang, Yuanyuan
    Nassif, Michael E.
    Chan, Paul S.
    Arnold, Suzanne V.
    Jones, Philip G.
    Spertus, John A.
    [J]. JAMA CARDIOLOGY, 2017, 2 (12) : 1315 - 1321
  • [35] Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction An Exploratory Analysis of a Phase 3 Randomized Clinical Trial
    Docherty, Kieran F.
    Jhund, Pardeep S.
    Claggett, Brian
    Ferreira, Joao Pedro
    Bengtsson, Olof
    Inzucchi, Silvio E.
    Kober, Lars
    Kosiborod, Mikhail N.
    Langkilde, Anna Maria
    Martinez, Felipe A.
    Ponikowski, Piotr
    Sabatine, Marc S.
    Sjostrand, Mikaela
    Solomon, Scott D.
    McMurray, John J. V.
    [J]. JAMA CARDIOLOGY, 2021, 6 (11) : 1298 - 1305
  • [36] Rationale and design of ENDEAVOR: A sequential phase 2b-3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction
    Lund, Lars H.
    Lam, Carolyn S. P.
    Pizzato, Patricia E.
    Gabrielsen, Anders
    Michaelsson, Erik
    Nelander, Karin
    Ericsson, Hans
    Holden, Julie
    Folkvaljon, Folke
    Mattsson, Andrea
    Collen, Anna
    Aurell, Malin
    Whatling, Carl
    Baldus, Stephan
    Drelich, Grzegorz
    Goudev, Assen
    Merkely, Bela
    Bergh, Niklas
    Shah, Sanjiv J.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (09) : 1696 - 1707
  • [37] Long -Term Effects Of Atrial Shunt Device On Cardiac Structure And Function In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: Results From The REDUCE LAP-HF II Randomized Clinical Trial
    Shah, Sanjiv J.
    [J]. JOURNAL OF CARDIAC FAILURE, 2024, 30 (01) : 313 - 313
  • [38] Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial (vol 324, pg 1512, 2020)
    Armstrong, P. W.
    Lam, C. S. P.
    Anstrom, K. J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (05): : 494 - 494
  • [39] A propitious time for initiating clinical trials in patients with heart failure with reduced ejection fraction and an estimated glomerular filtration rate <30 mL/min with an mineralocorticoid receptor antagonist and a K+ binder: 'the forbidden fruit'
    Epstein, Murray
    Pitt, Bertram C.
    [J]. EUROPEAN HEART JOURNAL, 2016, 37 (41) : 3130 - 3134
  • [40] RETRACTION: Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials (vol 17, pg 427, 2017) (Retraction of Vol 65, Pg 427, 2017)
    De Vecchis, Renato
    Ariano, Carmelina
    [J]. MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, 71 (05) : 609 - 609
12345